



Targeted Alpha Therapy (TAT): Progress in Radionuclide Production, Radiochemistry and Applications

Guest Editors:

Dr. Jean-François Gestin

Nantes Université, Inserm UMR
1307, CNRS UMR 6075, Université
d'Angers, CRCI2NA, F-44000
Nantes, France

Dr. Romain Eychenne

1. Groupement d'Intérêt Public
ARRONAX, 1 Rue Aronnax, F-
44817 Saint-Herblain, France
2. Nantes Université, Inserm UMR
1307, CNRS UMR 6075, Université
d'Angers, CRCI2NA, F-44000
Nantes, France

Deadline for manuscript
submissions:

closed (29 September 2023)

Message from the Guest Editors

Dear Colleagues,

In addition to imaging purposes, nuclear medicine offers promising therapeutic options based on the specific irradiation of malignant cells. This application is illustrated by the general concept of targeted radionuclide therapy (TRT) and applied by the use of radiopharmaceuticals which favor radionuclides able to transmit high energy to matter but with low penetration.

Among all the existing α -emitters, only few have suitable properties for potential clinical application. Although accessibility issues have hampered the development of radiopharmaceuticals for targeted alpha therapy (TAT), the better general knowledge acquired over the past few years has made α -emitters increasingly attractive. It is in this context that this Special Issue of *Pharmaceuticals* will be published, the main idea being to gather contributions in the form of research papers, short communications or review articles discussing radionuclides for TAT and covering production processes, radiochemistry or potential applications (preclinical, clinical and industrial).





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com